JP2022072433A - Percutaneous water evaporation inhibitor - Google Patents

Abstract

To provide a novel percutaneous water evaporation inhibitor and a moisturizing agent using the same.SOLUTION: Provided are: 1. a percutaneous water evaporation inhibitor containing lactic acid bacteria derived from ivy vine as an active ingredient; 2. the percutaneous water evaporation inhibitor according to above 1, wherein the lactic acid bacteria derived from ivy vine are lactic acid bacteria and/or a variant thereof; 3. a rough skin improver containing the percutaneous water evaporation inhibitor according to above 1 or 2 as an active ingredient; 4. a moisturizing agent containing the percutaneous water evaporation inhibitor according to above 1 or 2 as an active ingredient; 5. a horny layer moisturizing and barrier protein (involucrin, filaggrin, and transglutaminase 1) expression promoter with the lactic acid bacteria derived from ivy vine and/or a variant thereof as an active ingredient.SELECTED DRAWING: None

Description

There is an application for application of Article 30, Paragraph 2 of the Patent Act. Presentation by Exhibitors at the Food Development Exhibition on September 2, 2nd year of Reiwa (2020) https: // www. informa-japan. com / hi / seminar / present. php? _Ga = 2.11593084.932877770.10604281293-1082705831.1604281293

The present invention relates to a transdermal water evaporation inhibitor. The present invention is widely used in foods and drinks, pharmaceuticals, quasi-drugs, supplements, cosmetics and the like.

Maintaining and improving the condition of the skin has become a matter of concern for both men and women of all ages. The transepidermal water loss, also abbreviated as TEWL (trans epidermal water loss), is used for skin barrier evaluation, and it is evaluated that keeping TEWL low is evaluated as having a high barrier.

In order to enhance the barrier of the skin, Patent Document 1 proposes an external skin preparation containing an extract of a plant belonging to the genus Plum of the Rosaceae family as a substance for further enhancing the TEWL inhibitory action of an organically modified clay mineral. Further, in Patent Document 2, TEWL is suppressed by using a propylene polymer having a weight average molecular weight of 25,000 to 100,000 and a melting point of 60 ° C. to 100 ° C., a hydrocarbon oil having a melting point of less than 60 ° C., and a hydrocarbon oil having a melting point of less than 60 ° C. at 25 ° C. An oil-in-water emulsified composition containing a paste-like ester oil and having a total oil content of 5 to 20% by mass and a content ratio of the paste-like ester oil to the total oil amount of 10 to 50% by mass. It has been proposed (Patent Document 3).

Ulcerative colitis and Crohn's disease are intractable among inflammatory bowel diseases (IBD), whose etiology is not yet clear. Factors related to inflammatory bowel disease include abnormalities in the intestinal flora, impaired secretory IgA production of intestinal epithelial cells, and cytokines under the intestinal mucosa (Patent Document 4).
It is also known that Lactobacillus casei strain GG has the potential to increase the IgA immune response in the intestine, thereby enhancing the intestinal immunological barrier, and by nasal administration of Lactobacillus rhamnosus GG, respiratory organs. It has also been reported that enhanced cell-mediated immunological responses in mice protect mice from influenza virus infection. As a result, IgA is known to have a function of protecting against influenza infection and the like, and also having a function of protecting a foreign substance of a virus in the oral cavity (Patent Document 4).

Japanese Unexamined Patent Publication No. 2007-153809 Japanese Unexamined Patent Publication No. 2016-79183 Japanese Unexamined Patent Publication No. 2018-177764 Japanese Unexamined Patent Publication No. 2018-008980

Against this background, the present inventor has an effect of suppressing the amount of transdermal water evaporation from lactic acid bacteria derived from kudzu vine, and has an effect of promoting the expression of proteins for improving skin barrier function (expression levels of involucrin and filaggrin, transglutaminase 1). And completed the present invention. In addition, through clinical trials, it was found that it has an effect of suppressing transepidermal water loss, an effect of improving collagen density, and an effect of increasing IgA, and completed the present invention.
That is, an object of the present invention is to provide a novel transdermal water evaporation inhibitor, a protein expression promoter for improving skin barrier function, an IgA increasing agent, a collagen density improving agent, and a barrier improving agent using these. ..

The features of the present invention for solving the above problems are as follows.
1. 1. A transdermal water evaporation inhibitor containing lactic acid bacteria (Leuconostoc mesenteroides) derived from kudzu vine as an active ingredient.
2. 2. The above-mentioned 1. The transdermal water evaporation inhibitor according to.
3. 3. Above 1. Or the above 2. A rough skin improving agent containing the percutaneous water evaporation inhibitor described in the above as an active ingredient.
4. Above 1. Or the above 2. A moisturizer containing the transdermal water evaporation inhibitor described in 1 as an active ingredient.
5. Lactic acid bacterium derived from kudzu vine (Leuconostoc mesenteroides) (Patent Microbial Deposit Center Accession No .: NITE P-02751) Strain and / or its mutant strain as an active ingredient in the stratum corneum moisturizing / barrier protein (involucrin, filaggrin, transglutaminase 1) Expression promoter.
6. Lactic acid bacterium derived from kudzu vine (Leuconostoc mesenteroides) (Patent Microorganism Depositary Center Accession No .: NITE P-02751) A dermal collagen density improving agent containing a strain and / or a mutant strain thereof as an active ingredient.
7. Lactic acid bacterium derived from kudzu vine (Leuconostoc mesenteroides) (Patent Microorganism Depositary Center Accession No .: NITE P-02751) A skin quality improving agent containing a strain and / or a mutant strain thereof as an active ingredient.
8. An IgA-increasing agent containing a strain of Leuconostoc mesenteroides (Patent Microorganism Depositary Center, Accession No .: NITE P-02751) and / or a mutant strain thereof as an active ingredient.

It is a graph which shows the transdermal moisture evaporation suppression effect (before SDS application) of "Kuzunotsuru lactic acid bacterium". It is a graph which shows the transdermal moisture evaporation suppression effect (after application of SDS) of "Kuzunotsuru lactic acid bacterium". It is a graph which shows the transdermal water evaporation amount suppressing action (change amount before and after SDS application) of "Kuzunotsuru lactic acid bacterium". It is a graph which shows the transdermal moisture evaporation suppression effect (difference between the coated part and the unapplied part after SDS application) of "Kuzunotsuru lactic acid bacterium". It is a graph which shows the skin involucrin mRNA expression level of "Kuzunotsuru lactic acid bacterium". It is a graph which shows the expression level of the skin filaggrin mRNA of "Kuzunotsuru lactic acid bacterium". It is a graph which shows the skin transglutaminase 1 mRNA expression level of "Kuzunotsuru lactic acid bacterium". The nucleic acid sequence of the 16S rDNA gene of the "Kuzunotsuru lactic acid bacterium" strain is shown. The 16S rDNA gene of the "Kuzunotsuru lactic acid bacterium" strain (sequence of SIID23149-01 in the upper row) and RIB belonging to Leuconostoc masteroides to be compared. It is an alignment comparing with 9186 strains (obtained from Liquor Research Institute, sequence of SIID23149-02 in the lower row). The 1243th nucleic acid is "G" in SIID23149-01, whereas it is "A" in SIID23149-02 (described separately in FIGS. 9A to 9C). The 16S rDNA gene of the "Kuzunotsuru lactic acid bacterium" strain (sequence of SIID23149-01 in the upper row) and RIB belonging to Leuconostoc masteroides to be compared. It is an alignment comparing with 9186 strains (obtained from Liquor Research Institute, sequence of SIID23149-02 in the lower row). The 1243th nucleic acid is "G" in SIID23149-01, whereas it is "A" in SIID23149-02 (described separately in FIGS. 9A to 9C). The 16S rDNA gene of the "Kuzunotsuru lactic acid bacterium" strain (sequence of SIID23149-01 in the upper row) and RIB belonging to Leuconostoc masteroides to be compared. It is an alignment comparing with 9186 strains (obtained from Liquor Research Institute, sequence of SIID23149-02 in the lower row). The 1243th nucleic acid is "G" in SIID23149-01, whereas it is "A" in SIID23149-02 (described separately in FIGS. 9A to 9C). It is a simple molecular phylogenetic tree based on the nucleic acid sequence of the 16S rDNA gene of the "Kuzunotsuru lactic acid bacterium" strain. It is a graph which shows the change amount of the placebo group and the lactic acid bacterium intake group of TEWL (cheek) in the "Kuzunotsuru lactic acid bacterium" clinical trial. It is a graph which shows the change amount of the placebo group and the lactic acid bacterium intake group of TEWL (arm) in the "Kuzunotsuru lactic acid bacterium" clinical trial. It is a graph showing the amount of change in the placebo and lactic acid bacteria intake group of saliva IgA in the "Kuzunotsuru Lactic Acid Bacteria" clinical trial. It is a graph which shows the change amount of Dermalabo (collagen score) in the "Kuzunotsuru lactic acid bacterium" clinical trial.

Hereinafter, the present invention will be described in detail.
The present invention is characterized in that it contains a lactic acid bacterium (Leuconostoc mesenteroides) derived from kudzu vine as an active ingredient.

Kudzu is a climbing plant of the leguminous family, and its roots are widely used as a raw material for Chinese herbs such as Kakkonto and as a raw material for kudzu starch known as Yoshino kudzu. Kuzunohana has been widely used since ancient times as a raw material for Chinese herbs for the purpose of preventing hangovers, vines as kudzu cloth and crafts, and leaves as feed for livestock. The lactic acid bacterium derived from the kudzu vine (Leuconostoc mesenteroides) is not particularly limited as long as it is obtained from the kudzu vine, but is a lactic acid bacterium (Leuconostoc mesenteroides) (Patent Microorganism Depositary Center Trust No. NITE P-02751) strain and. The mutant strain is preferred. This is because it has an excellent effect of suppressing the amount of transepidermal water loss.

The method for obtaining the lactic acid bacterium (Patent Microorganism Depositary Center Accession No .: NITE P-02751) strain is to accumulate and culture the kudzu vine in a liquid medium for lactic acid bacteria supplemented with an antibiotic at 25 ° C to 37 ° C for 24 to 48 hours. , The obtained culture solution can be obtained by smear culture on a BCP-added plate count agar medium and select 5 new vine strains (patented microorganism deposit center accession number: NITE P-02751) belonging to Leuconostoc mastereoides. can.

The lactic acid bacterium "Leuconostoc mesenteroides" isolated from the vine of kudzu (Leuconostoc mesenteroides) (Lactic acid bacterium of Patent Microbial Deposit Center: NITE P-02751) Typical culture conditions (also referred to as "Kuzunotsuru lactic acid bacteria") are, but are not limited to, static culture in MRS medium at 25 to 37 ° C. for 24 to 48 hours.

(Mycological characteristics)
The novel "Kuzunotsuru lactic acid bacterium" (accession number NITE P-02751) belonging to the Leuconostoc mesenteroides of the present invention has the following mycological characteristics characteristic of Leuconostoc mesenteroides and is used for fermented foods such as sauerkraut. This bacterium had the following mycological characteristics.
-Gram-positive cocci in the form of chains or diplococci.
-It is classified as a heterolactic acid bacterium that decomposes sugar to produce lactic acid bacteria and short-chain fatty acids other than lactic acid bacteria such as acetic acid, ethanol, and CO ₂ .
(Definition of terms)
The following is a list of definitions of terms specifically used herein.
As used herein, the term "heated cells" refers to cells that have been sterilized by heating after culturing. Although not limited, it typically refers to cells that have been cultured at 20 to 40 ° C. for 10 to 40 hours and then sterilized by heating at 70 to 121 ° C. for 10 to 60 minutes.

Variant strains of "Kuzunotsuru Lactic Acid Bacteria" are produced, for example, by subjecting them to general mutation treatment, adaptation by subculture, or natural mutation.
The mutation treatment can be performed using a common mutagen. Examples of the mutagen include a drug having a mutagen action, ultraviolet rays, and the like. Examples of the drug having a mutagenic effect include nucleotide base analogs such as streptomycin, ofloxacin, ethylmethanesulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, bromouracil, and acridines. ..

The transdermal water evaporation inhibitor of the present invention can be used as a material for various foods and drinks. Foods and drinks include, for example, confectionery (gum, candy, caramel, chocolate, cookies, snacks, jelly, gummy, tablet confectionery, etc.), noodles (soba, udon, ramen, etc.), dairy products (milk, ice cream, yogurt, etc.) , Etc.), seasonings (miso, soy sauce, etc.), soups, beverages (juice, coffee, tea, tea, carbonated beverages, sports beverages, etc.) and other general foods, health foods (tablets, capsules, etc.), nutrition Supplements (nutrition drinks, etc.) can be mentioned. It is advisable to appropriately add the transdermal water evaporation inhibitor of the present invention to these foods and drinks.

Various ingredients can be added to these foods and drinks depending on the type, for example, glucose, fructose, sucrose, maltose, sorbitol, stebioside, corn syrup, lactose, citric acid, tartrate acid, malic acid, and succinic acid. Acid, lactic acid, L-ascorbic acid, dl-α-tocopherol, sodium erythorbicate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, Arabic gum, Food materials such as carrageenan, casein, gelatin, pectin, agar, vitamin Bs, nicotinic acid amides, calcium pantothenate, amino acids, calcium salts, pigments, fragrances and preservatives can be used.

As a specific manufacturing method, a transdermal moisture evaporation inhibitor is spray-dried or freeze-dried together with powdered cellulose, and this is easily contained in foods and drinks (instant foods, etc.) by making it into powder, granules, tableting or solution. Can be made to. Further, the percutaneous water evaporation inhibitor can be dissolved in, for example, fats and oils, ethanol, glycerin or a mixture thereof to make a liquid, and added to a beverage or added to a solid food. If necessary, it can be mixed with a binder such as gum arabic or dextrin to form a powder or granules, and can be added to a beverage or a solid food.

When the transdermal water evaporation inhibitor of the present invention is applied to foods and drinks, it is preferable that the total content of the active ingredient in the foods and drinks is 1 to 20 wt% or less.

The transdermal water evaporation inhibitor of the present invention may be used as a material for drugs (including pharmaceuticals and quasi-drugs). It can be produced by appropriately blending the transdermal water evaporation inhibitor of the present invention with a raw material for a pharmaceutical preparation. Examples of the pharmaceutical raw materials that can be blended in the transdermal water evaporation inhibitor of the present invention include excipients (dextrose, lactose, sucrose, sodium chloride, starch, calcium carbonate, kaolin, crystalline cellulose, cacao butter, hardened vegetable oil, etc. Kaolin, talc, etc.), binder (distilled water, physiological saline, ethanol water, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, potassium phosphate, polyvinylpyrrolidone, etc.), disintegrant (sodium alginate, canten) , Sodium hydrogen carbonate, calcium carbonate, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose, gum arabic powder, gelatin, ethanol, etc.), disintegration inhibitor (white sugar, stear, cacao butter, hydrogenated oil, etc.), absorption promoter (Quady ammonium base, sodium lauryl sulfate, etc.), adsorbents (glycerin, starch, lactose, kaolin, bentonite, calcium acid, etc.), lubricants (purified talc, stearate, polyethylene glycol, etc.), etc. ..

The method for administering the transdermal water evaporation inhibitor of the present invention is generally oral administration in the form of tablets, pills, soft / hard capsules, fine granules, powders, granules, liquids and the like. It can be administered parenterally, but it may also be administered parenterally. When administered as a parenteral agent, it may be administered as a solution, or with the addition of dispersants, suspensions, stabilizers, etc., by local tissue administration, intradermal, subcutaneous, intramuscular and intravenous injection, etc. can. It may also be in the form of a suppository or the like. Furthermore, it can be administered as an eye drop.

The dose may vary depending on the administration method, medical condition, age of the patient, etc., but for adults, usually 0.5 to 200 mg of the active ingredient per day can be administered, and for children, usually about 0.5 to 50 mg can be administered.
The compounding ratio of the transdermal water evaporation inhibitor can be appropriately changed depending on the dosage form, but usually, when administered orally or by mucosal absorption, it is about 0.3 to 15.0 wt%, parenterally administered. In the case of, it is preferable to set it to about 0.01 to 10 wt%. Since the dose varies depending on various conditions, a dose smaller than the above dose may be sufficient, or it may be necessary to administer beyond the range.

The transdermal water evaporation inhibitor of the present invention can be expected to have a transdermal moisture evaporation inhibitory effect even when used as a skin external preparation (including cosmetics, pharmaceuticals and quasi-drugs).
Examples of the form of the external skin preparation containing the percutaneous water evaporation inhibitor of the present invention include milky lotion, soap, wash pigment, bathing agent, cream, milky lotion, lotion, eau decolon, shaving cream, and shaving. Lotion, cosmetic oil, sunscreen / sunscreen lotion, white powder, foundation, perfume, pack, nail cream, enamel, enamel remover, eyebrow, blush, eye cream, eye shadow, mascara, eyeliner, lipstick, lip cream, Examples include shampoo, rinse, hair dye, dispersion, and cleaning agent. In addition, examples of the pharmaceutical products or quasi-drugs to which the transdermal water evaporation inhibitor of the present invention can be added include ointments, creams, and external liquids.

In addition to the transdermal water evaporation inhibitor according to the present invention, the above-mentioned form of the skin external preparation may be added to skin external preparations such as cosmetics and non-pharmaceutical products as long as the percutaneous water evaporation inhibitory effect is not impaired. Contains ingredients, oils, higher alcohols, fatty acids, UV absorbers, powders, pigments, surfactants, polyhydric alcohols / sugars, polymers, physiologically active ingredients, solvents, antioxidants, fragrances, preservatives, etc. be able to. Examples are listed below, but the invention is not limited to these examples.

(1) Examples of oil content Ester-based oil phase components: glyceryl tri2-ethylhexanate, cetyl 2-ethylhexanate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isostearic acid Isocetyl, butyl stearate, butyl myristate, ethyl linate, isopropyl linoleate, ethyl oleate, isosetyl myristate, isostearyl myristate, isostearyl palmitate, octyldodecyl myristate, isosetyl isostearate, diethyl sevacinate, adipine Diisopropyl acid, isoaraquil neopentanoate, glyceryl tri (capril capric acid), trimethylolpropane tri2-ethylhexanoate, trimethylolpropane triisostearate, pentaerythritol tetra2-ethylhexanoate, cetyl caprylate, decyl laurate, Hexil laurate, decyl myristate, myristyl myristyl, cetyl myristate, stearyl stearate, decyl oleate, cetyl lysinoreate, isostearyl laurate, isotorideyl myristate, isosetyl myristate, isosteyl myristate, isosetyl palmitate, Isostearyl palmitate, octyl stearate, isosetyl stearate, isodecyl oleate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, cetostearyl 2-ethylhexanoate, stearyl 2-ethylhexarate, hexyl isostearate, Ethylene glycol dioctarate, ethylene glycol diolaneate, propylene glycol dicaprate, propylene glycol di (capril capric acid), propylene glycol dicaprylate, neopentyl glycol dicaprate, neopentyl glycol dioctarate, glyceryl tricaprylate, glyceryl triundecyl, Glyceryl triisopalmitate, glyceryl triisostearate, octyldodecyl neopentaate, isostearyl octanoate, octyl isononanoate, hexyldecyl neodecanoate, octyldodecyl neodecanoate, isosetyl isostearate, isostearyl isostearate, octyldecyl isostearate, poly Glycerin oleic acid ester, polyglycerin isostearic acid ester, charcoal Dipropyl acid, dialkyl carbonate (C12-18), triisocetyl citrate, triisoaraquil citrate, triisooctyl citrate, lauryl lactate, myristyl lactate, cetyl lactate, octyl decyl lactate, triethyl citrate, acetyltriethyl citrate, citrate Acetyltributyl acid, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, dioctyl sevacinate, cholesteryl stearate, cholesteryl isostearite, hydroxysteer Examples thereof include cholesteryl acid, cholesteryl oleate, dihydrocholesteryl oleate, phytosteryl isostearate, phytosteryl oleate, isocetyl 12-stearoyl hydroxystearate, stearyl 12-stearoyl hydroxystearate, and isostearyl 12-stearoyl hydroxystearate.
Hydrocarbon-based oil phase components: squalane, liquid paraffin, α-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybutene, microcrystalline wax, petrolatum and the like can be mentioned.
Animal and vegetable oils and their hardened oils, and naturally occurring waxes: beef oils, hardened beef fats, pork fats, hardened pork fats, horse oils, hardened horse oils, mink oils, orange raffy oils, fish oils, hardened fish oils, egg yolk oils and other animal oils. Its hardened oil, avocado oil, almond oil, olive oil, cacao butter, kiwi seed oil, apricot oil, kukui nut oil, sesame oil, wheat germ oil, rice germ oil, rice bran oil, safflower oil, shea butter, soybean oil, evening primrose oil , Perilla oil, brown seed oil, camellia oil, corn oil, rapeseed oil, hardened rapeseed oil, palm kernel oil, hardened palm kernel oil, palm oil, hardened palm oil, peanut oil, hardened peanut oil, castor oil, hardened castor oil , Sunflower oil, grape seed oil, jojoba oil, hardened jojoba oil, macadamia nut oil, medhome oil, cottonseed oil, hardened cottonseed oil, palm oil, hardened palm oil and other vegetable oils and their hardened oils, beeswax, high acidity beeswax, lanolin, reduction. Examples thereof include waxes such as lanorin, hardened lanorin, liquid lanorin, carnauba wax and montan wax.
Silicone-based oil phase components: dimethylpolysiloxane, methylphenylpolysiloxane, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, methylhydrogenpolysiloxane, polyether-modified organopolysiloxane, dimethyl Siloxane / methylcetyloxysiloxane copolymer, dimethylsiloxane / methylstealoxysiloxane copolymer, alkyl-modified organopolysiloxane, terminal-modified organopolysiloxane, amino-modified silicone oil, amino-modified organopolysiloxane, dimethiconol, silicone gel, acrylic Examples thereof include silicone, trimethylsiloxysilicic acid, and silicone RTV rubber.
Fluorine-based oil phase components: perfluoropolyether, fluorine-modified organopolysiloxane, fluoride pitch, fluorocarbon, fluoroalcohol, fluoroalkyl / polyoxyalkylene co-modified organopolysiloxane, and the like can be mentioned.

(2) Examples of higher alcohols Examples of higher alcohols include lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, behenyl alcohol, 2-ethylhexanol, hexadecyl alcohol, octyldodecanol and the like.

(3) Examples of fatty acids Caprylic acid, capric acid, undecylenic acid, lauric acid, myristic acid, palmitoleic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, araquinic acid, arachidonic acid, behenic acid , Erucic acid, 2-ethylhexanoic acid and the like.

(4) Examples of UV absorbers Paraaminobenzoic acid, amyl paraaminobenzoate, ethyldihydroxypropyl paraaminobenzoate, glyceryl paraaminobenzoate, ethyl paraaminobenzoate, octylparaaminobenzoate, octyldimethyl paraaminobenzoate, ethylene glycol salicylate, salicylate Octyl, triethanolamine salicylate, phenyl salicylate, butylphenyl salicylate, benzyl salicylate, homomentyl salicylate, benzyl silicate, octyl paramethoxycinerate, 2-ethylhexyl paramethoxycinerate, mono 2-ethylhexyl benzoate Glyceryl ethylhexanate, isopropyl paramethoxycinerate, diethanolamine paramethoxyhydrosilicate diethanolamine salt, diisopropyl diisopropyl silicate ester mixture, urocanic acid, ethyl urocanate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and its salts, Dihydroxymethoxybenzophenone, dihydroxymethoxybenzophenone sodium disulfonate, dihydroxybenzophenone, dihydroxydimethoxybenzophenone, hydroxyoctoxybenzophenone, tetrahydroxybenzophenone, butylmethoxydibenzoylmethane, 2,4,6-trianilinino-p- (carbo-2-ethylhexyl-) 1-oxy) -1,3,5-triazine, 2- (2-hydroxy-5-methylphenyl) benzotriazole, methyl-O-aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, Phenylbenzoimidazole sulfate, 3- (4-methylbenziliden) camphor, isopropyldibenzoylmethane, 4- (3,4-dimethoxyphenylmethylene) -2, 5-dioxo-1-imidazolidinepropionate 2-ethylhexyl, etc., and Examples thereof include these polymer derivatives and silane derivatives.

(5) Examples of powders and pigments Red No. 104, Red No. 201, Yellow No. 4, Blue No. 1, Black No. 401, etc., Yellow No. 4 AL Lake, Yellow No. 203 BA Lake, etc., Nylon powder , Silk powder, Urethane powder, Teflon (registered trademark) powder, Silicone powder, Polymethylmethacrylate powder, Cellulose powder, Steel, Silicone elastomer spherical powder, Polymers such as polyethylene powder, Yellow iron oxide, Red iron oxide, Black Colored pigments such as iron oxide, chromium oxide, carbon black, ultramarine blue and dark blue, white pigments such as zinc oxide, titanium oxide and cerium oxide, constitutional pigments such as talc, mica, sericite, kaolin and barium plate sulfate, mica titanium Pearl pigments such as barium sulfate, calcium carbonate, magnesium carbonate, aluminum silicate, metal salts such as magnesium silicate, inorganic powders such as silica and alumina, aluminum stearate, magnesium stearate, zinc palmitate, zinc myristine, myristin. Examples thereof include metal powders such as magnesium acid, zinc laurate, zinc undesylene and the like, bentonite, smectite, boron nitride and the like. There are no particular restrictions on the shape (spherical, rod-shaped, needle-shaped, plate-shaped, indefinite-shaped, flaky, spindle-shaped, etc.) and particle size of these powders. These powders are treated with conventionally known surface treatments such as fluorine compound treatment, silicone treatment, silicone resin treatment, pendant treatment, silane coupling agent treatment, titanium coupling agent treatment, oil treatment, N-acylated lysine treatment, and the like. It may or may not be surface-treated in advance by polyacrylic acid treatment, metal silane treatment, amino acid treatment, lysine treatment, inorganic compound treatment, plasma treatment, mechanochemical treatment, or the like.

(6) Examples of surfactants Anionic surfactants: fatty acid salts, α-acyl sulfonates, alkyl sulfonates, alkylallyl sulfonates, alkylnaphthalene sulfonates, alkyl sulfates, POE alkyl ether sulfates , Alkylamide Sulfate, Alkyl Phosphate, POE Alkylphosphate, Alkylamide Phosphate, Alkyylalkyl Taurine Salt, N-Acyl Amino Acid Salt, POE Alkyl Aether carboxylate, Alkyl Sulfonuccinate, Alkyl Sulfo Acetate Examples thereof include sodium, an acylated hydrolyzed collagen peptide salt, and a perfluoroalkyl phosphate ester.
Cationic surfactants: alkyltrimethylammonium chloride, stearyltrimethylammonium chloride, stearyltrimethylammonium bromide, cetostearyltrimethylammonium chloride, disstearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride, behenyltrimethylammonium bromide, benzalconium chloride , Amidopropyldimethylhydroxypropylammonium chloride behenic acid, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, quaternary ammonium salt of lanolin derivative and the like.
Amphoteric tensides: carboxybetaine type, amide betaine type, sulfobetaine type, hydroxysulfobetaine type, amide sulfobetaine type, phosphobetaine type, aminocarboxylate type, imidazoline derivative type, amidoamine type and the like can be mentioned.
Nonionic surfactants: propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, POE sorbitan fatty acid ester, POE sorbit fatty acid ester, POE glycerin fatty acid ester, POE akill ether, POE fatty acid ester, POE hardened sunflower Examples thereof include oil, POE castor oil, POE / POP copolymer, POE / POP alkyl ether, polyether-modified silicone lauric acid alkanolamide, alkylamine oxide, hydrogenated soybean phospholipid and the like.
Natural surfactants: lecithin, saponin, sugar-based surfactants and the like can be mentioned.

(7) Examples of polyhydric alcohols and sugars Ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, glycerin, diglycerin, polyglycerin, 3-methyl-1,3-butanediol, 1, 3 -Butylene glycol, sorbitol, mannitol, raffinose, erythritol, glucose, sucrose, fructose, xylitol, lactose, maltose, martitol, trehalose, alkylated trehalose, mixed isomerized sugar, sulfated trehalose, purulan and the like. Further, these chemically modified products and the like can also be used.

(8) Examples of polymers Acrylic acid ester / methacrylic acid ester copolymer (plus size, manufactured by Reciprocal Chemical Co., Ltd.), vinyl acetate / crotonic acid copolymer (resin 28-1310, manufactured by NSC), vinyl acetate / croton Acid / vinyl neodecaneate copolymer (28-2930, manufactured by NSC), methyl vinyl ether maleic acid half ester (Gantrez ES, manufactured by ISP), T-butyl acrylate / ethyl acrylate / methacrylic acid copolymer (rubimer) , BASF), Vinylpyrrolidone / Vinylacetate / Vinylpropionate copolymer (Rubiscol VAP, BASF), Vinylacetate / Crotonic acid copolymer (Rubiset CA, BASF), Vinylacetate / Croton Acid / vinylpyrrolidone copolymer (Rubiset CAP, manufactured by BASF), vinylpyrrolidone / acrylate copolymer (Rubiflex, manufactured by BASF), acrylate / acrylamide copolymer (Ultrahold, manufactured by BASF), vinyl acetate / Butylmaleate / isobornylacryllate copolymer (Advantage, manufactured by ISP), carboxyvinyl polymer (Carbopol, manufactured by BFGoodrich), acrylic acid / alkyl methacrylate copolymer (Pemulene, manufactured by BF Goodrich), etc. Anionic polymer compound, dialkylaminoethyl methacrylate polymer acetic acid amphoteric (Yukaformer, manufactured by Mitsubishi Chemical Corporation), octylacrylamide acrylate / hydroxypropyl acrylate / butylaminoethyl methacrylate copolymer (AMPHOMER, NSC) ) And other amphoteric polymer compounds, vinylpyrrolidone / dimethylaminoethylmethacrylate quaternary product (GAFQUAT, manufactured by ISP), methylvinylimidazolium chloride / vinylpyrrolidone copolymer (rubicote, manufactured by BASF), etc. Polymer compound, polyvinylpyrrolidone (Rubiscol K, manufactured by BASF), vinylpyrrolidone / vinyl acetate copolymer (rubiscol VA, manufactured by BASF), vinylpyrrolidone / dimethylaminoethyl methacrylate polymer (copolymer 937, manufactured by ISP) ), Nonionic polymer compounds such as vinyl caprolactam / vinylpyrrolidone / dimethylaminoethyl methacrylate copolymer (copolymer VC713, manufactured by ISP). In addition, cellulose or its derivatives, keratin and collagen or its derivatives, calcium alginate, purulan, agar, gelatin, tamarind seed polysaccharide, xanthan gum, carrageenan, high methoxyl pectin, low methoxyl pectin, guar gum, arabic rubber, crystalline cellulose, arabino. Naturally-derived high molecular compounds such as galactan, carrageenan, tragacanth gum, alginic acid, albumin, casein, curdlan, gellan gum, and dextran can also be preferably used.

(9) Examples of physiologically active ingredients Examples of the physiologically active ingredients include substances that give some physiological activity to the skin when applied to the skin. For example, whitening ingredients, immunostimulators, anti-aging agents, UV protection agents, slimming agents, tightening agents, antioxidants, hair growth agents, hair growth agents, moisturizers, blood circulation promoters, antibacterial agents, bactericides, desiccants, Examples thereof include cooling sensitizers, warming sensitizers, vitamins, amino acids, wound healing promoters, stimulant relievers, painkillers, cell activators, enzyme components and the like. Examples of these suitable compounding ingredients include, for example, Ashitaba extract, Avocado extract, Amacha extract, Artea extract, Arnica extract, Aloe extract, Anzu extract, Anzu kernel extract, Ginkgo extract, Wikyo extract, Ukon extract, Oolong tea extract, Agetsu. Extract, Echinashi leaf extract, Ogon extract, Oubaku extract, Ouren extract, Omugi extract, Otogirisou extract, Odorikosou extract, Dutch mustard extract, Orange extract, Seawater dried product, Seaweed extract, Hydrolyzed elastin, Hydrolyzed wheat powder, Hydrolyzed silk , Camomila extract, carrot extract, kawarayomogi extract, licorice extract, karukade extract, kakyoku extract, kina extract, cucumber extract, guanosine, kuchinashi extract, kumazasa extract, clara extract, walnut extract, grapefruit extract, clematis extract, chlorella extract, quail extract, Gentiana extract, tea extract, yeast extract, gobo extract, fermented rice bran extract, rice germ oil, comfrey extract, collagen, moss peach extract, saishin extract, psycho extract, saitai extract, salvia extract, sabonsou extract, sasa extract, sanzashi extract , Sansho extract, Shiitake extract, Jio extract, Shikon extract, Shiso extract, Shinanoki extract, Shimotsukesou extract, Shakuyaku extract, Shobu root extract, Shirakaba extract, Sugina extract, Seiyoukizuta extract, Seiyousanzashi extract, Seiyouniwatoko extract, Seiyounokogirisou extract Hakka extract, sage extract, zegna oyster extract, senkyu extract, senburi extract, soybean extract, taiso extract, thyme extract, tea extract, chowji extract, chigaya extract, chimpi extract, touki extract, tokinsenka extract, tounin extract, towhi extract, dokudami extract, tomato Extract, Natto extract, Carrot extract, Garlic extract, Novara extract, Hibiscus extract, Bakumondou extract, Parsley extract, Honey, Hamamelis extract, Parietaria extract, Hikiokoshi extract, Visabolol, Biwa extract, Fukitanpopo extract, Fukinoto extract, Bukuryo extract, Butcher Bloom extract, grape extract, propolis, hechima extract, benibana extract, peppermint extract, bodaiju extract, button extract, hop extract, pine extract, malonie extract, mizubasho Cucumber extract, Mukuroji extract, Melissa extract, Peach extract, Yagurumagiku extract, Eucalyptus extract, Yukinoshita extract, Yokuinin extract, Yomogi extract, Lavender extract, Apple extract, Lettuce extract, Lemon extract, Rengesou extract, Rose extract, Rosemary extract, Roman chamomile extract , Royal jelly extract and the like.
In addition, biopolymers such as deoxyribonucleic acid, mucopolysaccharide, sodium hyaluronate, sodium chondroitin sulfate, collagen, elastin, chitin, chitosan, hydrolyzed eggshell membrane, amino acids, hydrolyzed peptides, sodium lactate, urea, sodium pyrrolidone carboxylate. , Moisturizing ingredients such as betaine, whey, trimethylglycine, oily ingredients such as sphingolipids, ceramides, phytosphingosin, cholesterol, cholesterol derivatives, phospholipids, ε-aminocaproic acid, glycyrrhizinic acid, β-glycyrrhetinic acid, lysoteam chloride, guaiazulene, Immunostimulators such as hydrocortisone, vitamins such as vitamin A, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, calcium pantothenate, biotin, nicotinic acid amide, vitamin C ester, allantin, diisopropylamine dichloro Active ingredients such as acetate, 4-aminomethylcyclohexanecarboxylic acid, antioxidants such as tocopherol, carotenoid, flavonoid, tannin, lignan, saponin, cell activators such as α-hydroxy acid and β-hydroxy acid, γ-orizanol, Blood circulation promoters such as vitamin E derivatives, wound healing agents such as retinol and retinol derivatives, whitening agents such as arbutine, kodiic acid, placenta extract, sulfur, ellagic acid, linoleic acid, tranexamic acid and glutathione, cepharanthin, can elephant extract, Togarashi tinki, hinokithiol, garlic iodide extract, pyridoxin hydrochloride, DL-α-tocopherol, DL-α-tocopherol acetate, nicotinic acid, nicotinic acid derivative, calcium pantothenate, D-pantothenyl alcohol, acetylpantothenyl ethyl ether, biotin , Allantin, isopropylmethylphenol, estradiol, ethynyl estradiol, capronium chloride, benzalkonium chloride, diphenhydramine hydrochloride, takanal, camphor, salicylic acid, nonyl acid vanillylamide, nonanoic acid vanillylamide, pyrocton olamine, glyceryl pentadecanoate, L-menthol, Mononitroguayacole, resorcin, γ-aminobutyric acid, benzethonium chloride, mexiletin hydrochloride, auxin, female hormone, cantalist tincture, cyclosporin, zincpyrythion, hydrocortisone, minoxidyl, polyoxyethylene sorbitan monostearate, peppermint oil, sasani Hair growth agents such as shiki extract can be mentioned.

(10) Examples of antioxidants Sodium hydrogen sulfite, sodium sulfite, erythorbic acid, sodium erythorbicate, dilauryl thiodipropionate, tocopherol, trirubiguanide, nordihydroguayletic acid, parahydroxyanisole, butylhydroxyanisole, dibutylhydroxy Examples thereof include plant extracts having an antioxidant effect such as toluene, ascorbyl stearate, ascorbyl palmitate, octyl gallate, propyl gallate, carotenoid, flavonoid, tannin, lignan, saponin, apple extract and chowdi extract.

(11) Examples of solvents Purified water, ethanol, lower alcohols, ethers, LPG, fluorocarbons, N-methylpyrrolidone, fluoroalcohols, volatile linear silicones, next-generation freon and the like can be mentioned.

The transdermal water evaporation inhibitor of the present invention can be used as a raw material for food and drink compositions, chemical compositions, and external skin preparations.
As the pharmaceutical raw material that can be blended in these, the same ones as those used for the above-mentioned transdermal water evaporation inhibitor can be used, and the production method and the administration method are the same as those used for the transdermal water evaporation inhibitor. Can be used.

Hereinafter, examples of the present invention will be described. The examples shown below are for confirming various actions and effects of the transdermal water evaporation inhibitor obtained by the present invention, and the scope of the present invention is limited to these products and manufacturing methods. It is not something that will be done.

Example (1) Isolation of "Kuzunotsuru Lactic Acid Bacteria""Kuzunotsuru Lactic Acid Bacteria" belonging to Leuconostoc mastereoides was isolated by the following procedure.
・ Enrichment culture of kudzu vines in a liquid medium for lactic acid bacteria supplemented with antibiotics at 25 ° C to 37 ° C for 24 to 48 hours. Five new vines belonging to the above were selected.
The "Kuzunotsuru Lactic Acid Bacteria" belonging to the Leuconostoc masteroides obtained as described above was deposited at the National Institute of Technology and Evaluation Biotechnology Center Patent Organism Depositary (NITE-IPOD) on July 11, 2018 (NITE-IPOD). Accession number NITE P-02751).
(2) 16S rDNA gene analysis of "Kuzunotsuru Lactic Acid Bacteria" The nucleotide sequence of the isolated "Kuzunotsuru Lactic Acid Bacteria" 16S rDNA gene was determined. The result is shown in FIG. 8 (SEQ ID NO: 1). FIG. 9 shows the RIB. It is an alignment comparing with 9186 strains (obtained from Liquor Research Institute, SIID23149-02 in the lower row, SEQ ID NO: 2).
FIG. 10 is a simple molecular phylogenetic tree based on the nucleic acid sequence of the 16S rDNA gene of “Kuzunotsuru Lactic Acid Bacteria”. The upper left line is the scale bar, the numerical value located at the branch of the lineage branch is the bootstrap value, and the "T" at the end of the strain name indicates the reference strain (Type strine) of that kind.

Test Example 1: Percutaneous water evaporation (TEWL) evaluation test method of "Kuzunotsuru Lactic Acid Bacteria" For 28 days in hairless mice, "Kuzunotsuru Lactic Acid Bacteria" powder (Patent Microbial Deposit Center Contract No .: NITE NITE P-02751) (50 or 100 mg) / kg) was orally administered, and TEWL on the back skin was measured. Then, a sodium dodecyl sulfate aqueous solution (SDS solution) was applied to the right side of the median line for 5 minutes and wiped. The day after repeating this operation for a total of 3 days, TEWL was measured again. The next day, the skin was collected and the mRNA expression levels of involucrin, filaggrin and transglutaminase 1 were examined.
The results are shown in FIGS. 1 (before SDS coating), FIG. 2 (after SDS coating), FIG. 3 (change amount before and after SDS coating), and FIG. 4 (difference between coated and non-coated sites after SDS coating). In addition, FIG. 5 shows the expression level of involucrin, FIG. 6 shows the expression level of filaggrin, and FIG. 7 shows the expression level of transglutaminase 1. These are proteins present in the cornified envelope of the stratum corneum. Involucrin promotes keratinization of epidermal cells, filaggrin binds to keratin to strengthen the stratum corneum, and transglutaminase 1 promotes the formation of stratum corneum bridges.

Measurement results and effects of Examples in Test Example 1 As shown in FIGS. 1 and 2, it was confirmed that TEWL was suppressed by "Kuzunotsuru lactic acid bacteria" by administration, and TEWL was suppressed especially at the SDS application site. It was confirmed that. Further, as shown in FIG. 3, it was confirmed that the TEWL inhibitory action had an excellent concentration-dependent action at the SDS application site. In addition, as shown in FIG. 4, when the difference between the SDS-coated part and the non-coated part was examined, it was found that TEWL was significantly reduced at 100 mg / kg administration as compared with the control. Furthermore, as shown in FIGS. 5 and 7, the expression levels of involucrin and transglutaminase 1 increased significantly, and the expression level of filaggrin also showed an increasing tendency as shown in FIG. It is considered to increase the expression level of the stratum corneum protein involved in the barrier function.
From the above, it was confirmed that "Kuzunotsuru Lactic Acid Bacteria" is useful as a TEWL inhibitor, and thereby is useful as a moisturizer. In addition, it was confirmed that it is also useful as a rough skin improving agent because it suppresses TEWL especially at the SDS application site.

Test Example 2: "Kuzunotsuru Lactic Acid Bacteria" clinical trial
1. Test outline ・ Test period: 5 / 14-6 / 25 (6 weeks)
・ Subjects: 27 (male: 20; female: 8)
・ Study design: Double-blind comparative study (placebo group: 14 subjects, lactic acid bacteria group: 14 subjects)
One woman in the placebo group dropped out due to poor physical condition.
-Test method: Saliva IgA, dermal collagen density, TEWL (percutaneous water evaporation), questionnaire (questionnaire on skin quality). The dermis collagen density is a collagen score (in Dermalabo, it represents the density of collagen in the dermis. The larger the value, the richer the collagen and the better the condition of the dermis collagen). It was done by measuring.
* The questionnaire was created with reference to "Effects of defecation, stool properties, and skin quality by taking lactic acid bacteria fermented filtrate PS-B1" published in the Journal of the Japanese Society of Food and Beverage, Vol. 30, No. 3, 112-122 (2020). We asked you to answer the table shown in Table 1 below.
The results are shown in FIG. 11 (TEWL (cheek)), FIG. 12 (TEWL (arm)), FIG. 13 (saliva IgA), FIG. 14 (change amount of Dermalabo (collagen score)), and Table 2 (skin quality questionnaire). ..

Results and effects of Examples in Test Example 2 (1) Transepidermal water loss (TEWL) (cheek)
As shown in FIG. 11, both the placebo group and the lactic acid bacterium intake group significantly decreased in the 4-week (4W) intake and the 6-week (6W) intake in each group as compared with the pre-ingestion (0W). There was no significant difference between the groups, but there was a tendency for improvement in the lactic acid bacteria intake group. From this, it was confirmed that "Kuzunotsuru Lactic Acid Bacteria" has a TEWL improving effect on the cheeks.
(2) Percutaneous water evaporation (TEWL) (arm)
As shown in FIG. 12, both the placebo group and the lactic acid bacterium intake group showed a significant decrease in 4W intake and 6W intake in each group compared with before ingestion (0W), and there was no significant difference between the groups. However, there was a tendency for improvement in the lactic acid bacteria intake group. From this, it was confirmed that "Kuzunotsuru Lactic Acid Bacteria" has a TEWL improving effect on the arm as well.
(3) Saliva IgA
As shown in FIG. 13, the amount of IgA increased significantly at 4 W as compared with that before ingestion (0 W) only in the lactic acid bacteria intake group. There was no significant difference between the groups, but there was a tendency for IgA to increase in the lactic acid bacteria intake group (see Fig. 13). From this, it was confirmed that "Kuzunotsuru Lactic Acid Bacteria" has an IgA increasing effect.
(4) Dermalabo (dermis collagen density)
As shown in FIG. 14, the collagen score, which is an index showing the density of dermal collagen, was significantly increased in both 4W and 6W compared with those before ingestion (0W) only in the lactic acid bacteria ingestion group.
There was no significant difference between the groups, but there was an increasing tendency in the lactic acid bacteria intake group. From this, it was confirmed that "Kuzunotsuru Lactic Acid Bacteria" has an effect of improving the density of dermal collagen.

(5) Questionnaire (skin quality related)
As shown in Table 2, in the item of "glossy skin", only the lactic acid bacterium intake group showed a significant improvement at 4W as compared with before ingestion (0W), and there was a tendency for improvement at 6W.
In addition, in the item of "tight skin", only the lactic acid bacteria ingestion group significantly improved at 6W compared with before ingestion (0W).
In addition, in the item of "skin without color unevenness", only the lactic acid bacteria ingestion group tended to improve at 4W compared with before ingestion (0W).
Furthermore, in the item of "skin that does not cause stickiness", there was no significant difference in the lactic acid bacteria intake group, but the placebo deteriorated, whereas in the lactic acid bacteria intake group, there was no change, so comparison with placebo. Therefore, it can be said that there was a tendency for improvement.
In addition, in the item of "skin that does not care about dryness", only the lactic acid bacteria ingestion group was significantly improved by 4W and 6W compared with before ingestion (0W). From this result, it was confirmed that Kuzunotsuru lactic acid bacterium has a skin quality improving effect.

From the above results, in addition to the effect of improving transdermal water evaporation (TEWL) and collagen density and the effect of increasing saliva IgA, from the questionnaire (skin quality related), "Kuzunotsuru Lactic Acid Bacteria" has a W barrier function between skin and immunity. Was confirmed.

An example of compounding the percutaneous water evaporation inhibitor (“Kuzunotsuru Lactic Acid Bacteria”) according to the present invention is shown. The following formulation examples do not limit the present invention.
Formulation Example 1: Chewing gum
Sugar 53.0 wt%
Gum base 20.0
Glucose 10.0
Syrup 16.0
Fragrance 0.5
Percutaneous water evaporation inhibitor 0.5
100.0 wt%

Formulation example 2: Gummy
Reduced starch syrup 40.0 wt%
Granulated sugar 20.0
Buto sugar 20.0
Gelatin 4.7
Water 9.68
Yuzu juice 4.0
Yuzu flavor 0.6
Dye 0.02
Percutaneous water evaporation inhibitor 1.0
100.0 wt%

Formulation example 3: Candy
Sugar 50.0 wt%
Syrup 33.0
Water 14.4
Organic acid 2.0
Fragrance 0.2
Percutaneous water evaporation inhibitor 0.4
100.0 wt%

Formulation example 4: Yogurt (hard / soft)
Milk 41.5 wt%
Skim milk powder 5.8
Sugar 8.0
Agar 0.15
Gelatin 0.1
Lactic acid bacteria 0.005
Percutaneous water evaporation inhibitor 0.4
Fragrance trace amount
Water residue
100.0 wt%

Formulation example 5: Soft drink
Fructose-glucose liquid sugar 30.0 wt%
Emulsifier 0.5
Percutaneous water evaporation inhibitor 0.3
Appropriate amount of fragrance
Purified water residue
100.0 wt%

Formulation example 6: Tablet confectionery
Sugar 76.4 wt%
Glucose 19.0
Sucrose fatty acid ester 0.2
Percutaneous water evaporation inhibitor 0.5
Purified water 3.9
100.0 wt%

Formulation example 7: Soft capsule
Brown rice germ oil 47.0 wt%
Yuzu seed oil 40.0
Emulsifier 12.0
Percutaneous water evaporation inhibitor 1.0
100.0 wt%

Formulation Example 8: Tablets
Lactose 54.0 wt%
Crystalline cellulose 30.0
Starch decomposition product 10.0
Glycerin fatty acid ester 5.0
Percutaneous water evaporation inhibitor 1.0
100.0 wt%

Formulation example 9: Cosmetic cream squalane 20.0 wt%
Beeswax 5.0
Refined jojoba oil 5.0
Glycerin 5.0
Glycerin monostearate 2.0
Polyoxyethylene (20) Sorbitan-
Monostearate 2.0
Transdermal Moisture Evapotranspiration Inhibitor 2.0
Preservatives Appropriate amount Fragrance Appropriate amount
Purified water residue
100.0 wt%

Formulation example 10: Toner ethanol 5.0 wt%
Glycerin 2.0
1,3-butylene glycol 2.0
Polyethylene oleyl ether 0.5
Sodium citrate 0.1
Citric acid 0.1
Percutaneous water evaporation inhibitor 0.1
Purified water residue
100.0 wt%

Formulation example 11: Body gel macadamia nut oil 2.0 wt%
Octyldodecyl myristate 10.0
Methyl Phenyl Polysiloxane 5.0
Behenyl alcohol 3.0
Stearic acid 3.0
Bacil alcohol 1.0
Glyceryl monostearate 1.0
Polyoxyethylene sorbitol 2.0 with tetraoleate
Hydrogenated soybean phospholipid 1.0
Ceramide 0.1
Retinyl palmitate 0.1
Preservatives Appropriate amount of Centella asiatica extract 1.0
Percutaneous water evaporation inhibitor 1.0
1,3-butylene glycol 5.0
Purified water residue
100.0 wt%

Formulation example 12: Emulsion squalane 4.0 wt%
Vaseline 2.5
Cetanol 2.0
Glycerin 2.0
Oil-based glycerin monostearate 1.0
Stearic acid 1.0
L-Arginine 1.0
Percutaneous water evaporation inhibitor 0.5
Potassium hydroxide 0.1
Fragrance trace amount
Purified water residue
100.0wt%

Formulation Example 13: Bathing agent (liquid)
Propylene glycol 50.0 wt%
Ethanol 20.0
Sodium sulfate 5.0
Percutaneous water evaporation inhibitor 0.5
Lanolin 0.5
Avocado oil 0.5
Dye 1.5
Fragrance 22.0
100.0wt%

Based on the above, the present invention can provide a novel transdermal water evaporation inhibitor.

The "Tsuru 5" strain belonging to Leuconostoc masteroides was deposited on July 11, 2018 at the National Institute of Technology and Biotechnology Biotechnology Center Patent Organism Depositary (NITE-IPOD) (trust number NITE P-02751). ..

SEQ ID NO: 1: Nucleic acid sequence of 16S rDNA gene of "Tsuru 5" strain SEQ ID NO: 2: RIB belonging to Leuconostoc mastereoides. Nucleic acid sequence of 16S rDNA gene of 9186 strain

Claims (8)

A transdermal water evaporation inhibitor containing lactic acid bacteria (Leuconostoc mesenteroides) derived from kudzu vine as an active ingredient. The lactic acid bacterium (Leuconostoc mesenteroides) derived from the kudzu vine is the lactic acid bacterium (Leuconostoc mesenteroides) (Patent Microorganism Depositary Center Accession No .: NITE P-02751) strain and / or a mutant strain thereof. Percutaneous water evaporation inhibitor. A rough skin improving agent containing the transdermal water evaporation inhibitor according to claim 1 or 2 as an active ingredient. A moisturizer containing the transdermal water evaporation inhibitor according to claim 1 or 2 as an active ingredient. Leuconostoc mesenteroides derived from kudzu vine (Patent Microbial Deposit Center Accession No .: NITE P-02751) A stratum corneum moisturizing / barrier protein expression promoter containing a strain and / or a mutant strain thereof as an active ingredient. Lactic acid bacterium derived from kudzu vine (Leuconostoc mesenteroides) (Patent Microorganism Depositary Center Accession No .: NITE P-02751) A dermal collagen density improving agent containing a strain and / or a mutant strain thereof as an active ingredient. Lactic acid bacterium derived from kudzu vine (Leuconostoc mesenteroides) (Patent Microorganism Depositary Center Accession No .: NITE P-02751) A skin quality improving agent containing a strain and / or a mutant strain thereof as an active ingredient. An IgA-increasing agent containing a strain of Leuconostoc mesenteroides (Patent Microorganism Depositary Center, Accession No .: NITE P-02751) and / or a mutant strain thereof as an active ingredient.

Images